INVO Fertility Expands Services with PRP Therapy at Wisconsin Clinic

This analysis is based on the INVO Fertility press release [1] published on June 30, 2025, announcing the addition of Platelet-Rich Plasma (PRP) therapy capabilities at the Wisconsin Fertility Institute center.

INVO Fertility’s launch of PRP therapy represents a strategic expansion into the emerging regenerative fertility treatment segment. The therapy utilizes autologous blood-derived growth factors to stimulate tissue regeneration, targeting patients with specific fertility challenges including thin uterine lining and diminished ovarian reserve [1]. This positioning creates a mid-tier treatment option between basic fertility procedures and more invasive alternatives like egg donation or surrogacy.

The market context is favorable, with the global fertility market valued at $39.27 billion in 2025 and projected to reach $85.53 billion by 2034 (CAGR 9.03%) [4]. The U.S. fertility market specifically is expected to grow from $9.00 billion to $19.72 billion by 2034 (CAGR 9.10%) [4]. This expansion aligns with INVO Fertility’s strategy to increase revenue per patient through advanced treatment options [1].

However, the company faces significant financial headwinds, with a market capitalization of approximately $2.01-3.65 million and substantial net losses of $28.19 million over the trailing twelve months [3]. The stock has exhibited extreme volatility, trading in a 52-week range of $0.45-$37.44 [3], reflecting market uncertainty about the company’s prospects.

: The Human Fertilisation and Embryology Authority (HFEA) in the UK has classified PRP treatments as “add-ons with limited evidence,” noting insufficient research supporting improved pregnancy chances and potential safety concerns [7]. Dr. Gretchen Collins, INVO’s double board-certified specialist leading the PRP program, acknowledged the therapy is “experimental but promising” [1].

: While INVO appears to have first-mover advantage in Wisconsin for PRP therapy [1], competitors like MCRM Fertility and Advanced Fertility Center of Chicago already offer similar services [5, 6]. The fertility clinic market shows rapid technology adoption patterns, suggesting INVO’s advantage may be temporary as competitors likely follow suit.

: The PRP therapy complements INVO’s existing INVOcell technology, creating a more comprehensive treatment portfolio [1]. This integration could improve patient retention within the INVO network and potentially increase treatment success rates, addressing both uterine and ovarian factors simultaneously.

: The limited clinical evidence supporting PRP efficacy presents significant adoption barriers [7]. Insurance coverage may be restricted due to the experimental classification, potentially limiting patient access and revenue potential.

: INVO’s precarious financial position, with substantial net losses and minimal market capitalization [3], raises questions about the company’s ability to invest in the necessary infrastructure and marketing for successful PRP therapy rollout.

: The fertility clinic industry historically shows rapid technology diffusion, suggesting competitors may quickly erode INVO’s first-mover advantage through price competition and similar service offerings.

: The expanding fertility market, particularly in the U.S. with 9.10% projected CAGR through 2034 [4], provides a favorable environment for innovative treatment adoption.

: PRP therapy positions INVO in the advanced treatment segment, potentially attracting patients seeking alternatives to conventional IVF but not ready for the most expensive options like egg donation [1].

: The addition of PRP therapy could increase average revenue per patient and improve treatment success rates, potentially addressing the company’s financial challenges through service expansion.

INVO Fertility’s PRP therapy launch represents a strategic move to capture growth in the expanding fertility treatment market while addressing the company’s financial challenges through service diversification. The therapy targets specific patient segments with thin uterine lining and diminished ovarian reserve [1], positioning it as an intermediate treatment option between basic procedures and invasive alternatives.

The global fertility market’s strong growth trajectory, projected to reach $85.53 billion by 2034 [4], provides a favorable backdrop for this expansion. However, limited clinical evidence supporting PRP efficacy [7] and INVO’s significant financial challenges [3] present substantial execution risks.

The success of this initiative will likely depend on several factors: clinical validation of PRP outcomes, insurance coverage decisions, competitive response timing, and INVO’s ability to effectively market the therapy to appropriate patient segments. The experimental nature acknowledged by company leadership [1] suggests a measured rollout approach may be prudent.